Wakamoto Pharmaceutical Co., Ltd.

As of March 31, 2026, Wakamoto Pharmaceutical Co., Ltd. carries a market capitalization of 12.18B, placing it among publicly traded companies globally. Its enterprise value stands at 10.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Wakamoto Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of March 31, 2026, Wakamoto Pharmaceutical Co., Ltd. has 34.71M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Wakamoto Pharmaceutical Co., Ltd. maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Wakamoto Pharmaceutical Co., Ltd.'s stock has gained approximately 3.07% over the past 52 weeks. The 50-day moving average sits at 295.52, while the 200-day moving average is 304.05.

As of March 31, 2026, Wakamoto Pharmaceutical Co., Ltd. holds 2.01B in cash and equivalents against 400.00M in total debt, resulting in a net debt position of -1.61B. Total book value stands at 12.01B, with working capital of 6.89B providing operational flexibility.

Wakamoto Pharmaceutical Co., Ltd.'s most recent stock split took place on September 26, 1995 with a 10:11 split ratio.